Wakui A
Miyagi Cancer Center, Natori, Japan.
Gan To Kagaku Ryoho. 1994 Oct;21(14):2398-406.
Cancer chemotherapy plays a central role in the treatment of recurrent or unresectable scirrhous gastric cancers classified mainly as Borrmann type 4. Though we have no specifically effective drugs for scirrhous gastric cancer, 5-FU and its derivative, MMC, anthracyclines, CDDP, CQ and ACNU are known to be relatively effective single agents against this tumor. In an attempt to enhance the effect of single agents, several combined chemotherapy regimens have been devised and tested. These regimens included 5-FU + MMC, UFT + MMC, UFT + CDDP, MTX.5-FU, FAM, FAP, EAP and ELF regimen. At present, combined therapies using 5-FU and MTX or CDDP may be the most attractive of these combined regimens.
癌症化疗在治疗主要归类为Borrmann 4型的复发性或不可切除的硬癌性胃癌中起着核心作用。尽管我们没有针对硬癌性胃癌的特效药物,但已知5-氟尿嘧啶及其衍生物、丝裂霉素、蒽环类药物、顺铂、卡莫司汀和阿糖胞苷是针对该肿瘤相对有效的单一药物。为了增强单一药物的疗效,人们设计并测试了几种联合化疗方案。这些方案包括5-氟尿嘧啶+丝裂霉素、优福定+丝裂霉素、优福定+顺铂、甲氨蝶呤.5-氟尿嘧啶、FAM、FAP、EAP和ELF方案。目前,使用5-氟尿嘧啶与甲氨蝶呤或顺铂的联合疗法可能是这些联合方案中最具吸引力的。